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ABSTRACT. Nuclear factor-kB (NF-kB)/Rel designates a family of transcription factors participating in the
activation of a wide range of genes crucially involved in immune and inflammatory function. NF-kB/Rel proteins
have been demonstrated recently in primary neurons and in several brain areas. Functional significance of these
proteins is still not understood completely, but since certain subsets of neurons appear to contain constitutively
active DNA-binding activity, it seems likely that they may participate in normal brain function. A growing body
of evidence is accumulating for a specific activation of NF-kB/Rel proteins in the CNS, and in particular in
neuronal cells, during neurodegenerative processes associated to etiologically unrelated conditions. Whether
NF-kB activation is part of the neurodegenerative process or of protective mechanisms is a matter of debate. This
issue will be reviewed here with particular attention to the available reports on the activity of NF-kB/Rel
proteins in both experimental paradigms of neurodegeneration and post-mortem brain tissue of patients affected
by various neurological diseases. We hypothesize that NF-kB/Rel proteins may represent the point of
convergence of several signalling pathways relevant for initiating or accelerating the process of neuronal
dysfunction and degeneration in many neurological diseases, including Parkinson’s disease, Alzheimer’s disease,
CNS viral infections, and possibly others. If NF-kB/Rel proteins represent an integrating point of several
pathways potentially contributing to neuronal degeneration, molecules that finely modulate their activity could
represent a novel pharmacological approach to several neurological diseases. BIOCHEM PHARMACOL 57;1:1–7,
1999. © 1998 Elsevier Science Inc.
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NF-kB§/Rel is a transcription factor that was first discov-
ered in the nuclei of mature B lymphocytes, where it bound
specifically to a decameric sequence (59-GGGACTTTCC-
39) in the kappa light chain enhancer region [1]. Over the
years, the NF-kB/Rel system has become recognized as a
central mediator of rapid and coordinated induction of
genes in response to external, primarily pathogenic stimuli.
Most of the genes known to be activated by NF-kB/Rel are
indeed involved in the immune and inflammatory re-
sponses or, more generally speaking, in response to stress.
An inappropriate regulation of NF-kB/Rel-mediated tran-
scription has also been associated with pathological condi-
tions including acute inflammatory reactions, toxic/septic
shock, acute phase reactions, atherosclerosis, radiation
damage, viral replication, myocardial infarction, and cancer
and in several neuropathologies (for review, see Refs. 2–4).
THE NF-kB/REL SYSTEM
Understanding the activation of NF-kB/Rel has become
increasingly complicated with the discovery of an entire
family of transcription factors that autoregulate themselves
through dimeric interaction and influence their own gene
expression. The major proteins belonging to the family of
NF-kB/Rel regulators include NF-kB1 (p50), NF-kB2
(p52), RelA (p65), relB, and c-rel. They all share the
presence of a Rel homology domain of about 300 amino
acids displaying a 35–61% identity between various family
members [2–4]. Unlike other transcription factors, NF-kB
proteins mainly reside in the cytoplasm in an inactive form
bound to an inhibitory protein referred to as IkB. Upon
appropriate stimulation, active NF-kB is released rapidly
from the cytoplasmic complex by phosphorylation and
ubiquination-dependent degradation of IkB. The IkB-re-
leased NF-kB dimer translocates to the nucleus, where it
binds cognate DNA sequences and activates transcription
of specific target genes. Members of the family can form
† Corresponding author: Mariagrazia Grilli, M.D., Schering-Plough Re-
search Center, San Raffaele Science Park, Via Olgettina 58, 20132 Milan,
Italy. Tel. 39-2-21219213; FAX 39-2-21219242; E-mail: mariagrazia.grilli@
spcorp.com
§ Abbreviations: AD, Alzheimer’s disease; APP, amyloid precursor pro-
tein; AT, ataxia telangiectasia; COX-2, cyclooxygenase-2; GM-CSF,
granulocyte, monocyte-colony stimulating factor; IL, interleukin; IRF,
interferon regulatory factor; LOX, lipoxygenase; MHC, major histocom-
patibility complex; NF-kB, nuclear factor-kappa B; PD, Parkinson’s
disease; ROS, reactive oxygen species; and TNF, tumour necrosis factor.
Biochemical Pharmacology, Vol. 57, pp. 1–7, 1999. ISSN 0006-2952/99/$–see front matter
© 1998 Elsevier Science Inc. All rights reserved. PII S0006-2952(98)00214-7
homo- and heterodimers between different subunits that
bind with different affinities to variants of the kB motif in
target genes. A further level of complexity in the system is
accomplished by different affinities of dimeric complexes
with different subunit composition for different members of
the IkB family. A great variety of signals has been reported
to activate NF-kB in several cell phenotypes. They include
inflammatory cytokines, phorbol esters, oxidative stress,
UV light, bacterial and viral products, and growth factors
[2–5]. How such diverse stimuli can ultimately result in
activation of NF-kB is not fully understood. Two second
messengers have gained consensus as final intracellular
mediators of NF-kB-activating stimuli: ROS (for review,
see Ref. 3) and ceramide [5].
NF-kB PROTEINS IN THE BRAIN
The finding that proteins belonging to the NF-kB family
are present in the CNS is relatively recent. The first report
of a kB-like activity in neurons came in 1993 from Rattner
and colleagues [6], who demonstrated that this activity
mediated neuronal HIV-1 promoter activation.
The presence of these transcriptional modulators in
neurons was then widely documented in vitro and in vivo, by
both immunolocalization studies and electrophoretic mo-
bility shift assays [7–11]. Of particular interest with regard
to the CNS location and function of NF-kB/Rel proteins
was the demonstration that unlike most of the cells in the
periphery, except for B lymphocytes, a high constitutive
NF-kB activity could be present in neurons. In particular,
nuclear NF-kB specific immunostaining appeared to be
present only in specific cellular subsets in rat cortex and
hippocampus [8]. In light of this observation, it was hypoth-
esized that the activation state of NF-kB might correlate
with neuronal activity and that the modulator might be
involved in regulation of the cellular antioxidant program
in metabolically very active neurons, such as those of the
cortex and hippocampus [5, 8]. A possible culprit under
those conditions could be identified in glutamate that at
nanomolar, non-toxic concentrations has been shown to
activate NF-kB in cerebellar granule cells [10, 11]. Neuro-
nal NF-kB inducible activity was demonstrated in neuronal
bodies and, intriguingly, also in synapses [7, 12] and in
postsynaptic densities [13], suggesting its role as a messenger
carrying synaptic information to the nucleus. It would be no
surprise, considering the role of NF-kB proteins in immune
function, if these proteins were also found in an inactive
cytoplasmic form in glial cells, including primary astrocytes,
astrocytoma cell line microglia, and Schwann cells [14–16].
As far as the nature of the signals that trigger NF-kB
activation within the CNS, they could be classified in two
major groups. The first includes signals that are active also
in the periphery, such as inflammatory cytokines (TNFa,
IL-1), phorbol esters, oxidative stress, UV light, and bac-
terial and viral products [2–5]. The second represents
CNS-specific signals, including depolarization, neurotrans-
mitters like glutamate [9, 10] and opioids [17], nerve growth
factor [18], and several diverse neurotoxic stimuli like
glutamate at micromolar concentrations [19, 20], glycated
tau [21], and b-amyloid [21–23]. A schematic representa-
tion of the NF-kB/Rel system operative in the CNS is
shown in Fig. 1. The number of genes relevant for CNS
function that might be regulated by members of the NF-kB
family is still limited [3, 4, 24, 25]. The list includes genes
encoding inflammatory cytokines (IL-6, TNFa, GM-CSF,
C-CSF), chemokines (MCP-1, IL-8), MHC class I, induc-
ible nitric oxide synthase, COX-2, manganese-superoxide
dismutase, APP, p53, and neuropeptides (dynorphin,
proenkephalin).
NF-kB AND NEUROPATHOLOGIES
A growing body of evidence is accumulating for a specific
activation of NF-kB/Rel proteins in both neuronal and
non-neuronal cells in neurodegeneration associated with
etiologically unrelated conditions.
NF-kB is activated in vivo in a number of model systems
of brain injury. Increased NF-kB DNA binding activity was
demonstrated in the ipsilateral cortex after traumatic brain
injury [26] and transient focal cerebral ischemia [27, 28], as
well as after seizures induced by kainate or pilocarpine [29,
30]. Activation of NF-kB was demonstrated in experimen-
tal allergic encephalitis, a well-characterized model of CNS
autoimmune injury, which is regarded as an animal model
of multiple sclerosis. The increase in transcription factor
activity strictly correlated with the course of clinical disease
and was localized to microglia, macrophages/monocytes,
and T lymphocytes [15].
NF-kB has also been shown to be activated in human
brains of patients affected by several neurological diseases.
The first report of NF-kB activation in brains of patients
affected by AD came from Yan et al. [21]. In particular, in
AD brains a specific activation of NF-kB p50 and p65 was
documented in neuronal subsets showing signs of degener-
ation like glycated tau accumulation. Immunohistochemi-
cal analysis of brain sections from AD patients revealed
that NF-kB p65 subunit was activated only in areas affected
by the disease [31] and in both neurons and astrocytes
surrounding early stage plaques [23]. This activation was
correlated to b-amyloid deposition since the peptide is a
potent NF-kB activator in vitro [23], possibly via interaction
with the receptor for advanced glycation end products
(RAGE) [22]. More recently, nuclear translocation of
NF-kB in cholinergic neurons of the nucleus basalis of
Meynert appeared to be increased significantly in AD
brains compared with age-matched controls [32]. The first
example of an NF-kB target gene with potential relevance
in AD was the APP gene, whose proteolytic product is
b-amyloid. Two stimuli potentially involved in neurode-
generation associated with AD, the inflammatory cytokine
IL-1b and the excitotoxin glutamate, were shown to
modulate NF-kB activity, interacting with the APP gene
promoter region [9, 19].
Immunohistochemical techniques were used to study the
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expression and cellular localization of NF-kB in mesence-
phalic dopaminergic neurons in PD patients and age-
matched controls. In PD patients, the number of neurons
with positive nuclei was 70-fold more than in control
subjects, suggesting that NF-kB translocation, which is
essential to its activation, was related to the pathophysiol-
ogy of PD [33].
Since the discovery of the role of NF-kB as a well-studied
regulator of viruses, its potential involvement in CNS viral
infections has been investigated. In particular, NF-kB has
an established role in the replication of HIV-1, which is
known to have profound effects in the brain, including
neurodegeneration (AIDS–dementia complex). NF-kB ac-
tivation in HIV-mediated CNS disease has been hypothe-
sized to contribute to the induction of cytokines such as
IL-6, TNFa, and GM-CSF, which could, in turn, be active
participants in the histopathological lesions and clinical
outcome of the disease [34]. A more direct role for NF-kB
in the neurodegeneration associated with HIV-1 infection
may also be hypothesized based on reports of a correlation
between its activation and neuronal dysfunction [20]. The
role of NF-kB family members in CNS viral infections is
likely to be much wider. Evidence for such a role has been
collected for at least another virus, the polyoma virus JC
[35]. AT is a human disease characterized by neurological,
immunological, and radiobiological problems, caused by a
mutation in the Atm protein kinase gene. Aberrant NF-kB
regulation, specifically a high constitutive activation, has
been found in fibroblasts from AT patients and demon-
strated to be implicated in their high sensitivity to ionizing
radiation [36, 37]. Recently, electron microscopic evidence
of neuronal degeneration in the cerebellar cortex of Atm
knockout mice was reported [38]. In light of these observa-
tions, a possible correlation between neurological deficien-
cies and NF-kB activation would certainly deserve more
extensive investigation.
In recent years, several clinical and experimental find-
ings have suggested that inflammation may be a common
component of several neurodegenerative conditions. In-
flammatory cells (activated microglia) and mediators (cy-
tokines, complement factors, acute phase reactants) are
indeed commonly found to be closely associated to degen-
erating neurons [39]. In such a respect, the role of NF-kB/
Rel proteins in neurodegenerative disorders may be greater
than expected. NF-kB proteins are, in fact, ideal mediators
of genetic programs underlying inflammation in CNS, since
they are activated by inflammatory signals and, in turn,
activate genes involved in inflammation [40]. On these
FIG. 1. Schematic representation of the extra- and intracellular signals that may activate the NF-kB/Rel system in neuronal cells.
Abbreviations: LPS, lipopolysaccaride; AGE, advanced glycation end products; RAGE, receptor for advanced glycation end products;
and IkB, inhibitor of kB proteins.
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bases, it could be proposed that NF-kB/Rel may represent
the point of convergence of multiple signalling pathways
relevant for initiating or accelerating the process of neuro-
nal dysfunction and degeneration in several neurodegen-
erative disorders.
NF-kB AND NEURONAL DEATH
The contribution of NF-kB family members to cell death
and cell survival pathways is an intriguing and debated
issue. We recently found that, at concentrations compatible
with plasma levels reached during the treatment of chronic
inflammatory states, salicylates may prevent glutamate-
induced cell death in primary cultures of cerebellar granule
cells and in hippocampal slices. The mechanism of action
of salicylates in preventing glutamate-induced neuronal
death appeared to correlate with the ability of these drugs
to inhibit the glutamate-induced activation of NF-kB
DNA-binding activity [20]. On the other hand, an anti-
apoptotic role of NF-kB has been documented in other
neuronal paradigms. NF-kB has been suggested to have a
role in the neuroprotection of hippocampal neurons, since
IkB antisense treatment resulted in an enhanced survival
after b-amyloid exposure [41]. Furthermore, soluble APP, a
neuroprotective product of APP metabolism, is an NF-kB
activator [42]. Apparently opposing roles of NF-kB/Rel
proteins in cell survival and death also have been reported
in the periphery and are efficaciously referred to as “Janus
faces” of NF-kB [43]. As suggested recently by Baichwal and
Baeuerle [44], NF-kB is probably important in determining
the fine balance between cell rescue and cell death that is
fundamental for the normal life of each organism, in several
cellular phenotypes. It is not clear, however, how cells
translate NF-kB activation in a program promoting death
or survival. At present, we can only speculate on factors
that may affect choice between death and survival effectors
in neuronal as well as in non-neuronal cells.
As previously underlined, NF-kB is not homogeneously
expressed in the brain, and it shows diversity in subunit
expression and subcellular compartmentation. In different
cells, the relative expression of the different members of the
NF-kB family may influence the composition of the dimers
and, as a consequence, the affinity of the activated complex
to specific DNA sequence motifs located in the regulatory
regions of different genes. Moreover, activation of distinct
patterns of genes by the simultaneous activation of other
regulatory transcription factors may certainly contribute to
opposite cell fates in different cell types but also within the
same cell type perhaps depending on activation and meta-
bolic state. Other actors may play a role on the same stage.
HMG-like proteins have been shown to determine whether
NF-kB may function as an activator or a repressor of
transcription [45]. One exciting prospect originating from
studies on CRE (cyclic AMP regulatory element)-mediated
transcription [46] is that spatially distinct intracellular
signalling may influence gene expression in a unique way.
This issue basically stands on the observation that synaptic
inputs that influence cytoplasmic and/or nuclear calcium
levels differentially regulate distinct programs of gene
expression and, therefore, distinct long-term neuronal
changes. Detailed studies on the correlation between spa-
tiotemporal dynamics in the activation of second messen-
gers, including ROS and ceramide subcellular generation,
and NF-kB function might disclose unexpected informa-
tion. Finally, another concept to be applied to this debated
issue is the concept of “threshold.” Activation of NF-kB-
mediated nuclear response may consist of a gradual recruit-
ment of genes as a function of the intensity and temporal
course of the triggering stimulus. This would imply a
hierarchy in the NF-kB dimeric complexes to be activated,
as well as in the genes whose transcription is initiated. For
example, the physiological activation of glutamate recep-
tors, which generates a short-lasting increase of intracellu-
lar calcium concentrations, may result in the activation of
a restricted number of transactivators, among which are
certain NF-kB complexes. Increasing glutamate concentra-
tions at the synaptic level and/or abnormally stimulating
glutamate receptors, as is likely to occur in some neuropa-
thologies, may result in the activation of a larger number of
transcription factors. These additional nuclear modulators,
coordinately with NF-kB, might extend the number and/or
amplify the level of transcription of NF-kB target genes to
finally alter the cellular response. The checkpoint that
discriminates between NF-kB-mediated physiological and
pathological responses may be cell-specific, influenced by
the nature and the intensity of the extracellular stimulus,
and able to be modified continuously by the constitutive
metabolic and functional context of the transcriptional
machinery.
PHARMACOLOGY OF THE NF-kB/REL SYSTEM
Since the discovery of the involvement of NF-kB in
different pathologies, as described above, molecules en-
dowed with the ability of interfering with NF-kB activation
and/or transcriptional activity have attracted great interest.
Although for the majority of these molecules the precise
mechanism and site of action are not completely clarified,
the inhibitory effects on the NF-kB system appear to
contribute to the large pharmacological spectrum of some
of them, such as immunosuppressants and anti-inflamma-
tory drugs.
Glucocorticoids are potent NF-kB inhibitors. Several
mechanisms potentially underlie this property. Activation
of glucocorticoid receptor was shown to induce transcrip-
tion of the IkBa gene [47, 48]. In addition, activated
glucocorticoid receptors directly interact with and inhibit
activated NF-kB subunits [49].
Among non-steroidal anti-inflammatory drugs, several
molecules have been shown to block activation of NF-kB
complexes. The mechanism of action of salicylates in
preventing NF-kB activation in T cells was suggested to be
inhibition of IkB phosphorylation and degradation [50]. In
primary neurons, the mechanism responsible for the inhi-
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bition of glutamate-induced NF-kB activation and neuro-
protection has not been investigated in detail. In light of
the different composition of the activated NF-kB com-
plexes in the two experimental paradigms, i.e. the p50–p65
heterodimer in HIV-long terminal repeat transfected T
cells and a p50 homodimer in cerebellar neurons [20], one
cannot exclude the possibility that diverse mechanisms of
action of salicylate in inhibiting NF-kB activation may take
place.
Tepoxaline, a dual COX/LOX inhibitor, appeared to
prevent cytokine-mediated NF-kB induction by reducing
the amount of available iron [51]. Iron chelation has also
been claimed for inhibition of NF-kB by deferoxamine [52].
Curcumin, an antitumour agent with anti-inflammatory
and anti-oxidant properties, inhibits TNF-mediated NF-kB
activation by preventing phosphorylation and degradation
of IkBa [53]. A direct physical interaction with NF-kB
subunits has been suggested for IRF-1 and -2 [54, 55] and for
epigallocatechin-3-gallate, potent antitumour agents with
anti-inflammatory and anti-oxidant properties [56].
The immunosuppressant cyclosporin A has been shown
to be capable of inhibiting lipopolysaccaride-induced
NF-kB activation. Apparently, cyclosporin A acts as a
noncompetitive inhibitor of the chymotrypsin-like activity
of the 20S proteasome, thereby inhibiting IkB degradation
[56]. Intriguingly, like salicylates, cyclosporin A has also
been shown to be neuroprotective [57].
IL-10 is a potent anti-inflammatory cytokine. It has been
shown to interfere with the activation of NF-kB, and this
activity has been correlated with its ability to block the
synthesis of other proinflammatory cytokines [58].
The tyrosine kinase inhibitor herbimycin A has been
shown to inhibit IL-1-induced NF-kB by covalently mod-
ifying the p50 subunit so as to interfere with its DNA
binding activity [59].
NO donors such as sodium nitroprussiate and S-nitroso-
N-acetylpenicillamine were shown to directly inhibit the
DNA-binding activity of NF-kB family proteins. A sug-
gested mechanism was S-nitrosylation of the C62 residue of
the p50 subunit [60]. Table 1 summarizes the proposed site
and mechanism of action of a number of NF-kB inhibitors.
CONCLUSIONS
The pharmacology of the NF-kB system is opening up
interesting perspectives in the development of novel strat-
egies for therapeutic intervention in different diseases
associated with an inflammatory response, including neu-
rodegenerative diseases. In fact, there is the possibility to
interfere at the nuclear level with the point of convergence
of different signalling pathways that are triggered by dis-
tinct pathogenetic stimuli and that are relevant in neuronal
dysfunction. Although the impact of the transcriptional
pharmacology approach in clinical use and, in particular, in
acute and chronic neurodegenerative disorders has still to
be evaluated, it certainly deserves great attention. At the
very least, we hope this speculative commentary may
provoke thought and discussion on the possible rationale
for developing inhibitors of NF-kB in the treatment of
neurodegenerative disorders.
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